Back
Compare AU
Compare YMAX vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares Aus Top 20 Eqy Yield Max Complex ETF (YMAX) and the Betashares Global Healthcare Currency Hedged ETF (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
YMAX | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 83 | 74 |
Median incremental investment | $1,080.50 | $745.07 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,295.60 | $1,592.71 |
Average age group | > 35 | > 35 |
Key Summary
YMAX | DRUG | |
|---|---|---|
Strategy | YMAX.AX was created on 2012-11-22 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 663.01m in AUM and 20 holdings. YMAX.AX aims to generate attractive quarterly income and reduce the volatility of portfolio returns by implementing an equity income investment strategy over a portfolio of the 20 largest blue-chip shares listed on the ASX. YMAX.AX does not aim to track an index. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | ALL AU 03/19/26 C52 (0 %) AS51 03/19/26 C9225 (0 %) ANZ AU 03/19/26 C42 (0 %) | AUD - AUSTRALIA DOLLAR (0 %) BRL - BRAZILIAN REAL (0 %) CHF - SWISS FRANC (0 %) |
Top 3 industries | Financials (44.88 %) Materials (16.70 %) Consumer Discretionary (8.57 %) | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) |
Top 3 countries | Australia (100.00 %) | United States (69.91 %) Switzerland (10.93 %) United Kingdom of Great Britain and Northern Ireland (7.38 %) |
Management fee | 0.76 % | 0.57 % |
Key Summary
YMAX | DRUG | |
|---|---|---|
Issuer | BetaShares | BetaShares |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | |
Asset class | ETF | ETF |
Management fee | 0.76 % | 0.57 % |
Price | $7.49 | $8.54 |
Size | $659.221 million | $176.152 million |
10Y return | -17.69 % | N/A |
Annual distribution yield (5Y) | 8.15 % | 1.92 % |
Market | ASX | ASX |
First listed date | 26/11/2012 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
YMAX | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 83 | 74 |
Median incremental investment | $1,080.50 | $745.07 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,295.60 | $1,592.71 |
Average age group | > 35 | > 35 |
Pros and Cons
YMAX | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
YMAX | DRUG |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |